These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21328579)

  • 1. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.
    Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.
    Vermeij R; Leffers N; Hoogeboom BN; Hamming IL; Wolf R; Reyners AK; Molmans BH; Hollema H; Bart J; Drijfhout JW; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2012 Sep; 131(5):E670-80. PubMed ID: 22139992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
    Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
    Zeestraten EC; Speetjens FM; Welters MJ; Saadatmand S; Stynenbosch LF; Jongen R; Kapiteijn E; Gelderblom H; Nijman HW; Valentijn AR; Oostendorp J; Fathers LM; Drijfhout JW; van de Velde CJ; Kuppen PJ; van der Burg SH; Melief CJ
    Int J Cancer; 2013 Apr; 132(7):1581-91. PubMed ID: 22948952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
    Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
    Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
    Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
    Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
    Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
    Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
    Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
    Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
    Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
    Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
    Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
    Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
    Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
    Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.
    Innamaa A; Jackson L; Asher V; Van Shalkwyk G; Warren A; Hay D; Bali A; Sowter H; Khan R
    Anticancer Res; 2013 Apr; 33(4):1401-8. PubMed ID: 23564779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of hypoxia inducible factors on the immune microenvironment in ovarian cancer.
    Duechler M; Peczek L; Szubert M; Suzin J
    Anticancer Res; 2014 Jun; 34(6):2811-9. PubMed ID: 24922644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
    Hasby EA
    Pathol Oncol Res; 2012 Apr; 18(2):509-18. PubMed ID: 22161157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
    Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Nijman HW; van Poelgeest MI; van Erkel AR; Smit VT; Daemen TA; van der Hoeven JJ; Melief CJ; Welters MJ; Kroep JR; van der Burg SH
    Oncotarget; 2015 Oct; 6(31):32228-43. PubMed ID: 26334096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
    Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
    van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
    Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report.
    Reinartz S; Boerner H; Koehler S; Von Ruecker A; Schlebusch H; Wagner U
    Hybridoma; 1999 Feb; 18(1):41-5. PubMed ID: 10211787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.